Protein kinases G as downstream mediators of the antifibrotic effects of stimulators of soluble guanylate cyclase by Matei, Alexandru-Emil
Proteinkinasen G als nachgeschaltete Mediatoren 
der antifibrotischen Effekte der löslichen 
Guanylylcyclase-Stimulatoren 
 
 
 
 
 
 
 
 
 
Der Medizinischen Fakultät  
der Friedrich-Alexander-Universität 
Erlangen-Nürnberg 
zur 
Erlangung des Doktorgrades Dr. med. 
 
 
 
 
 
 
 
 
 
 
 
 
 
vorgelegt von 
Alexandru-Emil Matei 
 
2 
 
Als Dissertation genehmigt von der 
Medizinischen Fakultät der Friedrich-Alexander-Universität 
Erlangen-Nürnberg 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vorsitzender des Promotionsorgans:  Prof. Dr. Markus F. Neurath 
 
Gutachter:        Prof. Dr. Jörg Distler 
 
Gutachter:      Prof. Dr. Georg Schett 
 
 
Tag der mündlichen Prüfung:    20. Dezember 2019 
 
3 
 
Inhaltsverzeichnis 
 
1. Abstract .................................................................................................................... 5 
2. Zusammenfassung ................................................................................................... 6 
3. Introduction ............................................................................................................. 8 
3.1. Systemic  sclerosis ................................................................................................ 8 
3.1.1. Definition.......................................................................................................... 8 
3.1.2. Pathogenesis .................................................................................................... 8 
3.1.3. Clinical manifestations of SSc ......................................................................... 11 
3.1.4. Therapy .......................................................................................................... 12 
3.1.5. The mouse model of bleomycin-induced skin fibrosis .................................. 14 
3.2. The NO-GC-cGMP-PKG signaling pathway ......................................................... 14 
3.3. sGC stimulators for the treatment of fibrosis .................................................... 15 
4. Materials and methods .......................................................................................... 17 
4.1. Patients .............................................................................................................. 17 
4.2. Cell culture ......................................................................................................... 18 
4.3. Quantitative PCR (qPCR) .................................................................................... 19 
4.4. Western blot analysis ......................................................................................... 19 
4.5. Luciferase reporter assay ................................................................................... 20 
4.6. cGMP concentration measurements ................................................................. 20 
4.7. Collagen measurements .................................................................................... 20 
4.8. Stainings of myofibroblasts ................................................................................ 20 
4.9. Immunofluorescence staining and analysis ....................................................... 21 
4.10. Knockout mice ................................................................................................ 21 
4.11. Experimental fibrosis ..................................................................................... 22 
4.12. Histology ........................................................................................................ 22 
4.13. Data presentation and statistical analysis ..................................................... 23 
5. Results .................................................................................................................... 23 
5.1. sGC-cGMP-PKG signaling is impaired in SSc ....................................................... 23 
5.2. Repetitive TGFβ stimulation leads to lower sGC-cGMP-PKG activity ................ 25 
5.3. sGC stimulators require PKG activity to inhibit TGFβ-induced fibroblast-to-
myofibroblast differentiation ........................................................................................ 25 
5.4. sGC stimulators require PKG activity to inhibit TGF-β induced collagen 
production ...................................................................................................................... 26 
4 
 
5.5. sGC-cGMP-PKG pathway interferes with fibroblast activation by modulating 
TGFβ-induced ERK activation ......................................................................................... 28 
5.6. Knockout of PKGs abrogates the antifibrotic effects of sGC stimulators .......... 33 
6. Discussion ............................................................................................................... 35 
7. References ............................................................................................................. 37 
8. Danksagung ......................................................... Fehler! Textmarke nicht definiert. 
9. Lebenslauf ........................................................... Fehler! Textmarke nicht definiert. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
1. Abstract 
Background and objectives. Systemic sclerosis (SSc) is a prototypical fibrotic disease 
with high morbidity and mortality. Effective antifibrotic therapies are not currently 
available for clinical practice. Stimulators of soluble guanylate cyclase (sGC) are 
currently evaluated in clinical trials for the treatment of fibrosis in SSc. We aimed in 
this work to evaluate the role of protein kinases G (PKG) as potential downstream 
mediators of sGC and of cyclic guanosine monophosphate (cGMP) and to 
characterize the dysregulation of this signaling pathway in SSc. 
Methods. Immunofluorescence and/or Western Blot were used to determine the 
expression levels of PKG 1 and 2, of sGC and of p-VASP and VASP. An ELISA kit was 
used to determine the levels of intracellular cGMP. The expression levels of the 
molecules above in human skin or in cultured fibroblasts was compared between 
healthy donors and SSc patients. 
Cultured fibroblasts from healthy donors, SSc patients or PKG 1 and 2 – double 
knockout mice were stimulated with TGF-β1 and/or treated with the sGC stimulator 
BAY 41-2272 or the PKG inhibitor KT5823. Stress fibers formation, the levels of α-
smooth muscle actin (α-SMA) protein, of Col1a1 mRNA and type 1 collagen protein 
were evaluated in treated cultured fibroblasts. 
Knockout mice for PKG1 and 2 were challenged with bleomycin and subsequently 
treated with BAY 41-2272. Skin thickness, hydroxyproline content and 
myofibroblast counts were determined to evaluate the fibrotic remodeling in these 
mice.  
Observations and results. We observed a dysregulation of the signaling pathway 
sGC-cGMP-PKG1 and 2 in SSc patients, for which the elevated levels of TGF-β1 could 
be responsible. sGC and cGMP are downregulated in SSc patients, whereas PKG1 
and 2 and upregulated, most likely as a futile compensatory mechanism. 
Fibroblast activation is inhibited by sGC stimulation by blocking TGF-β1-induced ERK 
activation, whereas inhibition or knockout of PKG 1 and 2 renders sGC stimulation 
ineffective.   
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Treatment with sGC stimulators protects wildtype mice, but not PKG1 and 2 – 
double knockout mice from bleomycin-induced fibrosis. 
Conclusions. We can conclude from our data that PKG 1 and 2 are essential 
downstream mediators of the antifibrotic effects of sGC stimulators, effects 
mediated by blocking TGF-β1-induced activation of ERK. We show moreover a 
reduced activity of the sGC-cGMP-PKG signaling pathway in SSc, likely induced by 
TGF-β1. 
 
2. Zusammenfassung 
 
Hintergrund und Ziele. Die Systemische Sklerose (SSc) ist eine prototypische 
fibrosierende Erkrankung, gekennzeichnet durch hohe Morbidität und Mortalität. 
Effektive antifibrotische Therapien sind bis jetzt für die klinische Anwendung nicht 
vorhanden. Stimulatoren der löslichen Guanylylcyclase (lGC, englisch sGC) werden 
derzeit in klinischen Studien für die Behandlung von Fibrose in SSc untersucht. Ziel 
dieser Arbeit war die Untersuchung der Rolle von Proteinkinasen G (PKG) als 
nachgeschaltete Mediatoren der sGC und des cyclischen Guanosinmonophosphat 
(cGMP) sowie die Charakterisierung der Fehlregulierung dieses Signalweges in SSc. 
Methoden. Zur Bestimmung der Expression von Proteinkinasen G 1 und 2, von sGC 
und von p-VASP und VASP wurden Immunfluoreszenz und/oder Western Blot 
eingesetzt, zur Bestimmung des Spiegels von intrazellulärem cGMP wurde ein ELISA 
Kit verwendet. Die Spiegel der oben genannten Proteine und Mediatoren in der 
Haut oder in kultivierten dermalen Fibroblasten bei gesunden Spendern wurden mit 
denen bei SSc Patienten verglichen.  
Kultivierte Fibroblasten von gesunden Spender, SSc Patienten oder PKG1 und 2 – 
Doppel-Knockout Mäusen wurden mit TGF-β1 und/oder dem sGC-Stimulator BAY 
41-2272, oder dem PKG-Inhibitor KT5823 behandelt. Bei den behandelten 
Fibroblasten wurde die Bildung von Stressfasern und die Menge von α-Smooth-
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Muscle-Actin (α-SMA) Protein, von Col1a1 mRNA und Kollagen Typ 1 Protein 
untersucht. 
Bei knockout Mäusen für PKG1 und 2 oder für sGC wurde Bleomycin appliziert, und 
diese anschließend mit BAY 41-2272 behandelt. Um die Fibrosebildung bei diesen 
Mäusen zu bestimmen, wurde die Hautdicke vermessen, der Hydroxyprolingehalt 
bestimmt und die Myofibroblastenanzahl quantifiziert. 
Ergebnisse und Beobachtungen. Wir stellten eine Fehlregulierung des Signalwegs 
sGC-cGMP-PKG1 und 2 bei den Patienten mit SSc fest, die auf die erhöhten TGF-β1-
Spiegel zurückzuführen zu sein scheint. sGC und cGMP sind bei SSc Patienten 
herunterreguliert. PKG1 und PKG2 sind hochreguliert, am ehesten als frustraner 
Kompensationsversuch. 
Die Fibroblastenaktivierung wird durch sGC Stimulierung und darauffolgende 
Hemmung der TGF-β1-induzierten ERK-Phosphorylierung gehemmt, wobei die 
Hemmung oder der Knockout der PKG1 und 2 den Effekt von sGC Stimulierung 
aufhebt.  
Behandlung mit sGC Stimulatoren schützt Wildtyp-Mäuse, aber nicht die PKG 1 und 
2 Doppel-Knockout Mäuse vor der durch Bleomycin-induzierten Fibrose.  
Schlussfolgerungen. Aus unseren Daten können wir schließen, dass PKG 1 und 2 
wesentliche nachgeschaltete Mediatoren der durch Hemmung der TGF-β1-
induzierten ERK-Phosphorylierung hervorgerufenen antifibrotischen Effekte von 
sGC Stimulatoren sind. Wir zeigen außerdem eine geringere Aktivität des 
antifibrotischen sGC – cGMP – PKG 1 und 2 Signalwegs in SSc, die wahrscheinlich 
von TGF-β1 induziert wird. 
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3. Introduction 
3.1. Systemic  sclerosis 
3.1.1. Definition 
SSc is a heterogeneous disease with a chronic-progressive evolution, 
characterized by a pathophysiological triad of microvascular lesions, autoimmunity 
and multiple organ fibrosis (Allanore et al. 2015). SSc is considered a prototypical 
fibrotic disease (Varga and Abraham 2007). 
3.1.2. Pathogenesis 
Although not completely elucidated, the etiology of SSc consists of an 
interplay between genetic, epigenetic and environmental factors (Allanore et al. 
2015). It is believed that environmental factors lead to vascular lesions in a 
genetically predisposed person, with subsequent activation of immune cells and 
fibroblasts. Activated fibroblasts deposit excess extracellular matrix (ECM), which 
leads to tissue fibrosis and organ disfunction. 
Part of the pathophysiological processes leading to fibrosis become 
autosustained in later stages of disease through dysregulations of signaling 
pathways and epigenetic factors (Gyorfi, Matei, and Distler 2018). 
Many cell types contribute to fibrogenesis: endothelial cells, thrombocytes, 
immune cells (B and T cells, monocytes, macrophages and dendritic cells), 
myofibroblasts and other cells that can differentiate in myofibroblasts (listed below) 
(Wynn and Ramalingam 2012). 
The first pathological changes appear in microvascular endothelial cells, as 
suggested by the fact that Raynaud phenomenon, a clinical manifestation of 
endothelial dysfunction, appears in many cases years before the first manifestations 
of tissue fibrosis (Trojanowska 2010). Lesions of endothelial cells lead to loss of 
capillaries with subsequent tissue hypoxia (Trojanowska 2010). Activated or 
apoptotic endothelial cells attract leukocytes that infiltrate the tissues and secrete 
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profibrotic factors. These factors lead to fibroblast activation and differentiation to 
myofibroblasts (the main effector cells  in fibrotic diseases) (Nicolosi et al. 2016). 
Both the innate and the adaptive immune responses are dystegulated in 
systemic sclerosis. Infiltrates of immune cells can be observed especially in early 
stages of SSc. These cells are important pathogenic players, especially through 
secretion of profibrotic mediators, such as TGF-β, IL-4, IL-13, IL-6, IL-1, platelet-
derived growth factor (PDGF) (Gabrielli, Avvedimento, and Krieg 2009).  
Characteristic autoantibodies (autoAb) directed against nuclear, nucleolar and 
surface antigens can be determined in sera of most SSc patients. These autoAbs 
have highly diagnostic and prognostic significance; however, their pathogenic role, 
especially in the case of autoAb directed against nuclear and nucleolar antigens, is 
mostly unknown. For some of the autoAbs directed against surface antigens (such 
as endothelin 1, PDGF und angiotensin II) there was described an activating role 
(Baroni et al. 2006; Kill et al. 2014). 
SSc is characterized by excessive accumulation of ECM components (especially 
of collagen, but also of elastin, fibronectin and proteoglycans) that leads to 
distruction of the healthy tissue architecture with subsequent organ failure and 
significant patient disability (Gabrielli, Avvedimento, and Krieg 2009). To the 
accumulation of ECM components contributes higher production, but also deficient 
degradation and enhanced crosslinking of ECM (mediated by prolyl- and 
lysyloxidase and transglutaminase 2) (Castelino and Varga 2014). 
Myofibroblasts are the most important effector cells in fibrotic diseases. They 
remodel tissues by producing high amounts of collagen and other ECM 
components; moreover, they characteristically express contractile proteins such as 
α-SMA and contract tissues. Many cell types can differentiate in myofibroblasts: 
resting fibroblasts, epithelial cell, endothelial cells, monocytes, pericytes, fibrocytes, 
smooth muscle cells, adipocytes and mesenchymal stem cells (Sun et al. 2016; Kim 
et al. 2006; Marangoni et al. 2015). 
Myofibroblasts appear only temporary in granulation tissue and are removed 
at the end of the process through programmed cell death or deactivation, whereas 
in fibrotic diseases they persist and maintain their active phenotype. The 
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mechanisms of fibroblast activation are similar in both processes. Fibrosis can be 
regarded for these reasons as a persistent, chronic wound healing process (Wynn 
and Ramalingam 2012).  
Signaling pathways regulated by TGF-β play a key role both in physiological 
wound healing processes and in fibrotic diseases. The essential role of TGF-β in 
fibrosis is highlighted by the fact that experimental overexpression of a 
constitutively active TGF-β receptor type I in murine skin or lung is sufficient to 
generate fibrosis in the respective organs (Sonnylal et al. 2007). Moreover, 
fibroblasts from healthy donors stimulated with TGF-β have an SSc-resembling 
phenotype. Preclinical studies showed that inhibition of TGF-β-regulated signaling 
pathways lead to a reduced fibrogenesis in different organs (Volkmann and Varga 
2019). 
TGF-β is part of a superfamily of growth factors and, beside its role in tissue 
repair and fibrosis, is involved in different other processes such as embryogenesis, 
immune modulation and angiogenesis (Blobe, Schiemann, and Lodish 2000; Chen 
and Ten Dijke 2016). TGF-β is produced and secreted in inactive form by 
thrombocytes, macrophages, T cells and fibroblasts among other cell types (Distler 
et al. 2017). Integrin αv is the main mediator of latent TGF-β activation. 
There are three subtypes of TGF-β receptors: TGFβRI, TGFβRII und TGFβRIII. 
TGF-β binds to TGFβRII and activates it – TGFβRII subsequently phosphorylates 
TGFβRI. TGFβRI phosporylates the canonical dowstream mediators SMAD2 and 
SMAD3, which then bind to SMAD4. This complex translocates in the cell nucleus, 
accumulates at SMAD-binding elements and influences gene expression (Massague 
2012). Moreover, many other non-canonical, SMAD-independent pathways like the 
mitogen-activated protein kinases ERK, P38 and JNK pathways, the phosphatidyl-
inositol-3-kinase/AKT or the Rho-like GTPase pathways can be activated by TGF-β 
binding to its receptor (Derynck and Zhang 2003).  
Figure 1 provides an overview of SMAD-dependent TGF-β signaling pathway 
and its interaction with the sGC-cGMP-PKG pathway. 
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Figure 1. The SMAD-dependent canonical TGF-β signaling pathway and its 
interaction with the sGC-cGMP-PKG signaling (adapted from Gyorfi AH, Matei AE, 
Distler JHW. Targeting TGF-beta signaling for the treatment of fibrosis. Matrix 
biology: journal of the International Society for Matrix Biology. 2018;68-69:8-27. ) 
 
3.1.3. Clinical manifestations of SSc 
The American College of Rheumatology (ACR)–European League Against 
Rheumatism (EULAR) criteria for the diagnosis of SSc, based on clinical 
manifestations, were published in 2013 (van den Hoogen, Khanna, Fransen, Johnson, 
Baron, Tyndall, Matucci-Cerinic, Naden, Medsger, Carreira, Riemekasten, Clements, 
Denton, Distler, Allanore, Furst, Gabrielli, Mayes, van Laar, Seibold, Czirjak, Steen, 
Inanc, Kowal-Bielecka, Muller-Ladner, Valentini, Veale, Vonk, Walker, Chung, Collier, 
Csuka, et al. 2013). SSc is, however, a very heterogeneous disease, and a more precise 
classification with further genetic or molecular criteria is needed. 
Skin fibrosis is characteristic for SSc. The extension and progression of skin 
fibrosis correlate with involvement of inner organs and patient survival (Domsic et al. 
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2011). Beside the skin, most frequently are the lungs, the heart, the gastro-intestinal 
tract and the musculoskeletal system affected (Gabrielli, Avvedimento, and Krieg 
2009). 
SSc can be classified according to extension of skin fibrosis in limited 
cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc). In lcSSc fibrosis affects the 
skin from fingers or toes, distal extremities until the elbow or knee and face. In 
dcSSc skin fibrosis extends beyond this to the proximal extremities and trunk (LeRoy 
et al. 1988). The evolution and possible complications of disease are very different 
between the two forms. In lcSSc the organ fibrosis is rather mild and appears only 
after years of disease evolution, whereas in patients with dcSSc both skin and organ 
fibrosis are evolving much faster. Pulmonary arterial hypertension (PAH) is more 
frequent in lcSSc, whereas renal complications appear more frequently in dcSSc 
(Ostojic et al. 2004). 
Extension and severity of skin fibrosis are evaluated with the modified Rodnan 
skin score (mRss). This score is used frequently in the clinical practice; however, the 
interobserver variability is high (Clements et al. 1995). The evolution of skin fibrosis 
in patients with dcSSc is highly variable, but follows usually a pattern with early 
progression, with subsequent plateau and late slow regression (Merkel et al. 2012). 
Lung complications, i.e. the PAH and the interstitial lung disease, are 
responsible for 50% of deaths due to SSc (Winstone et al. 2014). Many patients 
have, however, only mild interstitial lung disease, so that evaluation of fibrosis 
progression is of high importance.  
3.1.4. Therapy 
Therapeutical control of SSc is complicated by the diversity of pathogenical 
mechanisms and clinical manifestations. Currently there is no unified therapeutic 
approach with general applicability for all SSc patients. There are no approved 
targeted antifibrotic drugs and the therapeutic approaches are either 
immunosuppressant or are directed towards prevention or treatment of vascular 
complications (digital ulcerations, PAH, Raynaud phenomenon) (Volkmann and 
Varga 2019). Nevertheless, many promising molecules are in clinical trials for the 
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treatment of fibrosis (Table 1); many of them are targeting the TGF-β pathway 
(Gyorfi, Matei, and Distler 2018).  
 
Drug Targeted molecule Phase Identification 
number of the 
clinical study 
Status 
Riociguat  sGC agonist II NCT02283762 completed 
Nintedanib multiple tyrosine 
kinases 
III NCT03313180 completed 
Pirfenidone 
 
not clearly defined, 
but including TGF-β 
signaling 
II NCT03221257 recruiting 
Abatacept CTLA4 II NCT02161406 completed 
Tocilizumab IL-6 III NCT02453256 completed 
Lanifibranor 
(IVA337) 
PPARs II NCT02503644 completed 
GLPG1690 autotaxin II NCT03798366 recruiting 
IVIG Fc receptors? II NCT01785056 recruiting 
Tofacitinib JAK1/3 I/II NCT03274076 active, not 
recruiting 
GSK2330811 oncostatin I/II NCT03041025 recruiting 
AVID200 TGF-β1/TGF-β3 I  recruiting 
Brentuximab 
Vedotin 
CD30 I/II NCT03222492 recruiting 
Romilkimab 
(SAR 156597) 
IL4/IL13 II NCT02921971 active, not 
recruiting 
Lenabasum 
(JBT-101) 
CB2 Agonist III NCT03398837 active, recruiting 
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Table 1. Clinical studies in SSc 
 
3.1.5. The mouse model of bleomycin-induced skin fibrosis 
The mouse model of bleomycin-induced skin fibrosis is one of the most 
frequently used mouse model in SSc research. This model reproduces the 
inflammation-dependent early phases of SSc. Inflammation is essential for 
fibrogenesis. Bleomycin is repeatedly injected subcutaneously for 4 weeks, leading 
to leukocyte infiltration with subsequent skin fibrosis (Soare et al. 2016a). Systemic 
manifestations such as lung fibrosis or autoAb production could be proven in this 
model as well (Yamamoto et al. 1999). This mouse model is advantageous because 
of technical simplicity, however, it must be considered that factors that influence 
fibrogenesis can either have a direct effect on myofibroblasts or an indirect effect 
on inflammatory cells. 
3.2. The NO-GC-cGMP-PKG signaling pathway 
The nitric oxide (NO)-mediated signaling pathway is involved in many 
physiological processes such as thrombocyte aggregation or blood pressure 
regulation (the latter through relaxation of smooth muscle cells of blood vessels) 
(Groneberg et al. 2010; Walter and Gambaryan 2004).  
This signaling pathway starts at the different isoforms of NO-synthase that 
produce NO. NO binds to the NO-sensitive guanylate cyclase (NO-GC). NO-GC 
subsequently synthetises cGMP from guanosine triphosphate (GTP), which then 
activates multiple effectors, such as cGMP-regulated ion channels, cGMP-regulated 
phosphodiesterases (PDEs) or cGMP-dependent protein kinases (PKG) (Francis et al. 
2010). Signaling through this pathway is stopped by phosphodiesterases via 
degradation of cGMP. 
GCs are classified in two groups, depending on the molecules that activate 
them: the NO-GC and the peptide-activated GC (pGC). pGC can be activated by 
natriuretic peptides (Murad et al. 1978; Waldman, Rapoport, and Murad 1984). pGC 
is a cell membrane protein, whereas NO-GC is cytosolic and for this reason also 
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named soluble (sGC), although it can also be found in the cell membrane 
(Russwurm, Wittau, and Koesling 2001).  
The PDEs can be classified as cGMP-specific (PDE5, 6 and 9), cyclic adenosine 
monophosphate (cAMP)-specific (PDE 4, 7 and 8) and PDEs with dual specificity 
(Bender and Beavo 2006). 
PKGs were characterized as important downstream mediators of the sGC-
cGMP signaling pathway in the regulation of blood vessel tonus (Wegener et al. 
2002; Pfeifer et al. 1996). There are two PKGs, PKG 1 and 2, encoded by two 
different genes. PKG1 has, moreover, two isoenzymes as consequence of 
alternative splicing (Francis et al. 2005). Both isoenzymes bind two cGMP molecules 
pro monomer and phosphorylate similar substrates with comparable affinity 
(Hofmann et al. 2009). These isoenzymes are usually co-expressed, they are 
however in specific subcellular compartments and can translocate in other 
compartments after binding cGMP (Wilson et al. 2008; Casteel et al. 2008). cGMP is 
also not uniformly distributed in the cell, but is found in different cellular 
compartments at different concentrations (Fischmeister et al. 2006). 
Stable analogs of cyclic nucleotides are useful to research the effects of PKG 
or other protein kinases. These analogs translocate freely through the cell 
membrane and bind directly to PKG, some with higher activity than cGMP or 
resistance against PDE-mediated degradation and can thus help to distinguish 
between the effects of PKG and that of other molecules (Poppe et al. 2008).  
3.3. sGC stimulators for the treatment of fibrosis 
sGC is a known therapeutic target in the treatment of cardiovascular diseases. 
Its activity is clasically regulated either directly with inhalatory NO or indirectly with 
NO-releasing drugs (NO donors). These drugs have, however, numerous side 
effects. One of these is the NO reaction with reactive oxygen species leading to 
oxidative stress. This is particularly relevant for SSc, because oxidative stress leads 
to fibroblast activation (Gabrielli, Avvedimento, and Krieg 2009).  
These side effects can be avoided with the administration of direct, NO-
independent stimulators such as riociguat (Evgenov et al. 2006). Riociguat is 
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approved for the treatment of PAH including SSc-associated PAH (Ghofrani et al. 
2013; Humbert et al. 2017). 
Riociguat is currently in a clinical study for SSc patients called RISE-SSc (Distler 
et al. 2017). This therapy can be indicated especially for patients with coexisting 
important vascular and fibrotic changes. 
Studies from our group showed that sGC stimulators inhibit fibroblast 
activation in vitro and skin fibrosis in vivo. These effects are TGF-β-dependent via 
inhibition of TGF-β downstream mediator ERK. The antifibrotic effects are proven 
both in inflammation-driven and inflammation-independent mouse models (Beyer, 
Distler, and Distler 2012; Dees et al. 2015; Beyer, Zenzmaier, et al. 2015). The 
antifibrotic effects of sGC stimulators are cGMP-dependent and stronger than the 
effects of inhibitors of PDE5 (that lead also to higher cGMP levels through reduced 
degradation) (Dees et al. 2015; Beyer, Zenzmaier, et al. 2015). Other groups showed 
antifibrotic effects in mice models of kidney and liver fibrosis (Wang et al. 2006). 
The antifibrotic effects are dose-dependent and the doses used are good tolerated. 
However, detailed molecular mechanisms of the antifibrotic effects of sGC 
stimulators are unknown. This study extends the mentioned knowledge and studied 
the role of PKG 1 and 2 as downstream mediators of the antifibrotic effects of sGC 
stimulators (Matei et al. 2018). 
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4. Materials and methods 
 
4.1. Patients  
Skin biopsies of 15 SSc patients and 17 age- and sex-matched healthy controls were 
used for fibroblast isolation or stainings. All patients with SSc fulfilled the American 
College of Rheumatology/European League against Rheumatism criteria from 2013 
(van den Hoogen, Khanna, Fransen, Johnson, Baron, Tyndall, Matucci-Cerinic, Naden, 
Medsger, Carreira, Riemekasten, Clements, Denton, Distler, Allanore, Furst, Gabrielli, 
Mayes, van Laar, Seibold, Czirjak, Steen, Inanc, Kowal-Bielecka, Muller-Ladner, 
Valentini, Veale, Vonk, Walker, Chung, Collier, Ellen Csuka, et al. 2013). Seven 
patients had limited cutaneous disease (lcSSc), eight diffuse cutaneous disease 
(dcSSc). All patients with SSc and healthy volunteers provided written informed 
consent as approved by the Institutional Ethics Committee. 
 
Supplementary table 1: SSc patient information 
 
Characteristic 
 
Number 
 
Gender (f/m) 
 
9/6 
 
Age (median, range) 
 
45 (22-71) 
 
Disease subset (lcSSc/dcSSc) 
 
7/8 
 
Disease duration (years; median, range) 
  
6 (1-13) 
 
ANA positive 
 
15 
 
Anti-Scl70 positive 
 
5 
  
18 
 
Anti-centromere positive 4 
 
Anti-RNA polymerase positive 
 
1 
Pulmonary fibrosis 
 
9 
 
Pulmonary arterial hypertension 
 
1 
 
Myocardial involvement 
 
1 
 
Digital ulcers 
 
5 
 
 
4.2. Cell culture  
Fibroblasts were isolated and cultured as described (Beyer, Huang, et al. 2015). In all 
in vitro experiments, fibroblasts were serum starved for 24 hours, prior to treatment 
or analysis. In a subset of experiments, BAY 41-2272 and/or KT 5823 were added with 
fresh medium, and after another 2 hours, fibroblasts were stimulated with 
recombinant TGFβ1 (the predominant isoform in skin of SSc patients) (10ng/mL; R&D 
Systems, Abingdon, UK) (Gruschwitz et al. 1990). For analyses of collagen production 
(mRNA or protein) or stress fiber formation, cells were stimulated repetitively every 
12 h with TGFβ1 and lysed/fixed 48h after stimulation. Other particular experimental 
conditions are mentioned in the figure legends. Murine fibroblasts were isolated 
from the skin of mice with fibroblast-specific knockout of PKG1 and PKG2, and Cre-
mediated recombination was induced as described (Beyer, Zenzmaier, et al. 2015). 
The efficacy of knockout of PKGs in fibroblasts isolated from Col1a2;CreER x Prkg1fl/fl 
x Prkg2-/- mice by infection with a CRE-containing adenovirus was more than 80%. 
BAY 41-2272 and KT 5823 were purchased from Cayman Chemical (Ann Arbor, 
Michigan, USA). BAY 41-2272 was dissolved in dimethyl sulfoxide to a stock 
concentration of 10 mM and used for in vivo experiments at a concentration of 3 
mg/kg and in vitro at a concentration of 1 mM. KT 5823 was dissolved in ethyl acetate 
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to a stock concentration of 1 mM, and used for in vitro experiments at a 
concentration of 1 µM. The final concentrations of dimethyl sulfoxide or ethyl acetate 
in all experiments did not exceed 0.1%.  
 
4.3. Quantitative PCR (qPCR) 
Gene expression was quantified by SYBR Green real-time PCR using the ABI Prism 
7300 Sequence Detection System (Life Technologies, Darmstadt, Germany). Samples 
without enzyme in the reverse transcription reaction (non-RT controls) were used as 
negative controls (Zerr et al. 2015). Unspecific signals caused by primer-dimers were 
excluded by non-template controls and by dissociation curve analysis (Mallano et al. 
2016). β-actin was used to normalize for the amounts of cDNA within each sample. 
 
4.4. Western blot analysis 
Proteins were separated by sodium dodecyl sulfate/polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to a polyvinylidene difluoride membrane 
(PVDF) (Liang et al. 2017). The membrane was incubated with antibodies against PKGI 
(ab37709, Abcam, Cambridge, UK), PKGII (AP8001a, Abgent, San Diego, California, 
USA), sGC (160897, Ann Arbor, Michigan, USA), P-VASP - Ser239 (#3114, Cell 
Signaling, Leiden, Netherlands), VASP (#3112, Cell Signaling, Leiden, Netherlands), p-
cJUN (sc-822, Santa Cruz Biotechnology, Heidelberg, Germany), cJUN (32137, Abcam, 
Cambridge, UK), FRA2 (sc-13017, Santa Cruz Biotechnology, Heidelberg, Germany), 
p-SMAD (#9520, Cell Signaling, Leiden, Netherlands), p-ERK (#4370, Cell Signaling, 
Leiden, Netherlands), ERK (#9102, Cell Signaling, Leiden, Netherlands) , p-SRC (#2015, 
Cell Signaling, Leiden, Netherlands), SRC (44-656, Biosource International, Camarillo, 
California, USA), p-STAT3 (#9145, Cell Signaling, Leiden, Netherlands), STAT3 (#9139, 
Cell Signaling, Leiden, Netherlands), p-JNK (ab4821, Abcam, Cambridge, UK), JNK 
(#9252, Cell Signaling, Leiden, Netherlands), p-P38 (#9211, Cell Signaling, Leiden, 
Netherlands), P38 (#9212, Cell Signaling, Leiden, Netherlands), p-AKT (#4060, Cell 
Signaling, Leiden, Netherlands), AKT (#4691, Cell Signaling, Leiden, Netherlands) and 
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horseradish peroxidase (HRP)-conjugated secondary antibodies (Dako, Hamburg, 
Germany). β-actin served as loading control.  
 
4.5. Luciferase reporter assay 
Fibroblasts were transfected with luciferase reporter constructs under the control of 
repetitive Smad binding elements using the Cignal SMAD Reporter Assay Kit (LUC) 
(Qiagen, Hilden, Germany) and the Amaxa 4D-Nucleofector (Amaxa, Cologne, 
Germany). Transfection efficiency was determined by transfection with a positive 
control that contains a constitutively expressing firefly luciferase construct. Negative 
controls (non-inducible reporter constructs) were used to demonstrate the specificity 
of the effects. 
 
4.6. cGMP concentration measurements 
cGMP concentrations in lysates of culture fibroblasts were measured using the cGMP 
ELISA Kit according to the manufacturer’s instructions (Cayman Chemical, Ann Arbor, 
Michigan, USA). 
 
4.7. Collagen measurements 
Total soluble collagen in cell culture media was quantified by Sircol collagen assay 
(Biocolor, Belfast, UK). The total collagen content of tissue samples was determined 
by hydroxyproline assays (Palumbo-Zerr et al. 2017). 
 
4.8. Stainings of myofibroblasts 
Cultured fibroblasts fixed in 4% paraformaldehyde and permeabilised with 0.25% 
Triton X-100 or formalin-fixed, paraffin-embedded skin sections were stained with 
primary antibodies against α-smooth-muscle-actin (α-SMA) (A5228, Sigma-Aldrich, 
Steinheim, Germany) (Zhang et al. 2017). Alexa Fluor or HRP-conjugated antibodies 
(Life Technologies, Darmstadt, Germany) were used as secondary antibodies. Stress 
fibers were stained with rhodamine-conjugated phalloidin (Sigma-Aldrich). Nuclei 
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were counterstained using 4’,6-diamidino-2-phenylindole (Santa Cruz Biotechnology, 
Heidelberg, Germany) or hematoxylin. Myofibroblasts were counted as α-SMA-
positive, single cells in the dermis in immunohistochemistry stainings in a blinded 
manner in four random positions of each slide. 
 
4.9. Immunofluorescence staining and analysis 
Paraffin-embedded skin sections were stained with primary antibodies against PKG1 
(ab37709, Abcam, Cambridge, UK), PKG2 (PA5-50931, ThermoFisher Scientific, 
Waltham, Massachusetts, USA) and α-SMA (A5228, Sigma-Aldrich, Steinheim, 
Germany). Alexa Fluor-conjugated antibodies (Life Technologies, Darmstadt, 
Germany) were used as secondary antibodies. Nuclei were counterstained using 4’,6-
diamidino-2-phenylindole (Santa Cruz Biotechnology, Heidelberg, Germany) or 
hematoxylin. The fluorescence images were captured using a Nikon Eclipse 80i 
microscope (Nikon, Badhoevedorp, The Netherlands). Intensity of fluorescence 
signals was quantified using ImageJ. The same software was used for the generation 
of Voronoi tessellations, as follows: the DAPI channel was converted to a binary 
image; the nuclear signal was used as a seed for the automatic generation of a 
Voronoi cell (comprising all the points closer to this seed than to any other). Voronoi 
diagrams were quantitatively analyzed as follows: based on the intensity of the 
fluorescence signal, cells were defined as positive or negative; the corresponding 
Voronoi cells were colored in green (for positive cells) or grey (for negative cells). The 
resulting histograms are illustrative for the difference in number and distribution of 
positive cells in the dermis from SSc patients in comparison with healthy controls. 
 
4.10. Knockout mice 
Conditional knockout of sGC: To selectively inactivate sGC in fibroblasts, mice 
expressing conditional alleles encoding for the essential β1 subunit of sGC (GCfl/fl 
mice) were crossbred with Col1a2;CreER mice to generate Col1a2;CreER x GCfl/fl mice 
(Friebe et al. 2007).  
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Knockout of PKG1 and PKG2: Prkg1fl/fl mice  were crossbred with Col1a2;CreER mice 
to generate Col1a2;CreER x Prkg1fl/fl mice (Wegener et al. 2002). In contrast to sGC 
and PKG1, mice with ubiquitous knockout of PKG2 are viable (Pfeifer et al. 1996). We 
thus crossbred non-conditional Prkg2 knockout mice with Col1a2;CreER x Prkg1fl/fl 
mice to further generate Col1a2;CreER x Prkg1fl/fl x Prkg2-/- mice.  
Col1a2;CreER mice were kindly provided by Benoit de Crombrugghe (MD Anderson 
Cancer Center, Houston, Texas, USA).  
Cre-mediated recombination was induced by injecting tamoxifen intraperitoneally, 
at a dose of 1 mg/day for 5 consecutive days, at the age of 4 weeks. Control mice 
were injected with corn oil, the vehicle of tamoxifen.  
The knockout efficacy was over 80% in fibroblasts. 
 
4.11. Experimental fibrosis 
In the model of bleomycin-induced dermal fibrosis, fibrosis was induced in six-week-
old mice by subcutaneous injections of 100 µL of bleomycin (concentration of 0.5 
mg/mL) every other day for 4 weeks into defined areas of 1 cm2 at the upper back for 
4 weeks (Soare et al. 2016b). Subcutaneous injections of equal volumes of 0.9% NaCl 
served as control. 
To prevent gender biases, we included equal ratios of male and female mice in each 
in vivo experiment, as well as in each experimental group (Azzi et al. 2005; Czerniak 
2001). 
 
4.12. Histology 
Dermal thickness was assessed as the distance between the epidermal-dermal 
junction and the dermal-subcutaneous fat junction on hematoxylin-eosin stained 
sections at eight sites at 100-fold magnification. For direct visualization of collagen, 
trichrome staining was performed. 
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4.13. Data presentation and statistical analysis 
All data are presented as mean x-fold value relative to the control group ± SEM. The 
differences between the groups were tested for statistical significance by the Mann-
Whitney U non-parametric test (unless otherwise indicated). P values are expressed 
as follows: 0.05>p>0.01 as *; 0.01>p>0.001 as **; p<0.001 as *** (values less than 
0.05 were considered significant).   
 
5. Results 
5.1. sGC-cGMP-PKG signaling is impaired in SSc  
Using immunofluorescence staining we showed that the expression levels of 
both PKG1 and PKG2 are increased in the skin of SSc patients as compared to 
matched healthy controls (Fig. 2A). In the dermis, PKG1 and PKG2 were expressed 
not only in vessel-like structures, but also in spindle-shaped cells. We confirmed by 
costaining with αSMA that these spindle-shaped cells in the dermis with higher 
expression of PKG1 and PKG2 in SSc are myofibroblasts (Fig. 2B). 
 
 
Figure 2. PKG 1 and 2 are upregulated in skin of SSc patients and particularly in 
fibroblasts. (A, B) Immunofluorescence stainings for PKG1 and 2 in the skin of SSc 
patients and healthy controls: representative stainings (shown at 400× 
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magnification, scale bar size = 250 μm), histograms of fluorescence signals created 
from the Voronoi diagrams of these stainings, quantification of staining intensity (A) 
and costainings of PKG1 and PKG2 with αSMA (1000-fold magnification, scale bar 
size = 50 μm) (B) (n=5 for SSc and for healthy controls).  
 
The higher expression of PKG1 and PKG2 in SSc fibroblasts persisted after a few 
passages in cell culture (Fig. 3A). However, the expression levels of sGC were lower 
in SSc fibroblasts than in fibroblasts from healthy donors (Fig. 3B). We showed, 
moreover, lower levels of cGMP in SSc fibroblasts (Fig. 3C), suggesting a lower 
activation of the sGC-cGMP-PKG signaling pathway in SSc as a likely consequence of 
sGC downregulation. Vasodilator-stimulated-phosphoprotein (VASP) is an important 
substrate of PKGs and phosphorylation of VASP at Ser239 (P-VASP) is a common 
readout of PKG activity (Chettimada et al. 2012). Despite the increased expression of 
PKG1 and PKG2, the levels of P-VASP were decreased in SSc fibroblasts (Fig. 3D). The 
decreased levels of sGC, with lower levels of cGMP as main regulator of PKG activity, 
together with the reduced levels of P-VASP, suggest that PKG1 and PKG2 
upregulation in SSc is a futile attempt to compensate for the reduced sGC-cGMP-PKG 
activity.  
 
Figure 3. Cultured fibroblasts from SSc patients have higher expression of PKG1 
and 2, but lower levels of sGC with lower activity of sGC-cGMP-PKG pathway.  
Levels of PKG1 and PKG2 (A), of sGC (B), of cGMP (C) and of P-VASP (as a functional 
readout of PKG activity) in cultured fibroblasts isolated from the skin of SSc patients 
and healthy individuals. Representative western blots and quantification are shown 
for (C), (D) and (F) (n≥5 for SSc and for healthy controls). 
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5.2. Repetitive TGFβ stimulation leads to lower sGC-cGMP-
PKG activity  
We further showed that the changes in sGC-cGMP-PKG signaling observed in SSc 
fibroblasts are phenocopied by repetitive, long-term TGFβ stimulation: increased 
levels of PKG1 and PKG2, but lower levels of sGC, of cGMP and of P-VASP (Fig. 4A-D). 
Aberrant TGFβ signaling may thus drive the alterations of the sGC-cGMP-PKG 
pathway in SSc. 
 
Figure 4. Prolonged stimulation of dermal fibroblasts with TGFβ1 mimics the 
perturbation of sGC-cGMP-PKG signaling in SSc. Levels of PKG1 and PKG2 (A), of sGC 
(B), of cGMP (C) and of P-VASP (D) in fibroblasts upon chronic repetitive stimulation 
with TGFβ1 (every 12 hours for a total of 48 hours). Representative Western blots 
and quantifications are shown in A, B and D. n ≥ 5 for all experiments. 
 
5.3. sGC stimulators require PKG activity to inhibit TGFβ-
induced fibroblast-to-myofibroblast differentiation 
We previously demonstrated that sGC stimulators have antifibrotic effects by 
interfering with TGFβ signaling (Beyer et al. 2012). To evaluate if PKGs are involved in 
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these effects, we first inhibited PKG activity by the small molecule KT5823. While the 
sGC stimulator BAY41-2272 reduced TGFβ-induced stress fibers formation and αSMA 
expression, KT5823 abrogated these inhibitory effects of BAY41-2272 re-increased 
the levels of αSMA and the formation of stress fibers back to the levels of TGFβ-
stimulated fibroblasts in the absence of BAY41-2272 (Fig. 5).  
 
Figure 5. Inhibition of PKG prevents sGC stimulators from inhibiting TGFβ1-
induced myofibroblast differentiation. (A) Representative immunofluorescence 
stainings for αSMA and stress fibres (200× magnification) and (B and C) the 
respective quantification of αSMA and stress fibres signal intensity (n=3). 
 
5.4. sGC stimulators require PKG activity to inhibit TGF-β 
induced collagen production 
Incubation with BAY41-2272 or KT5823 did not interfere with COL1A1 mRNA or 
collagen protein production in resting fibroblasts. In TGFβ-stimulated fibroblasts 
from SSc patients, however, BAY41-2272 inhibited the upregulation of COL1A1 mRNA 
and of collagen protein, whereas co-incubation with KT5823 abrogated the inhibitory 
effects of sGC stimulation (Fig. 6). Similar findings were observed in healthy 
fibroblasts (Fig. 7).  
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Figure 6. Inhibition of PKG prevents sGC stimulators from inhibiting TGFβ1-
induced collagen production in SSc fibroblasts Levels of collagen protein (A) and 
COL1A1 mRNA (B) upon of pharmacological PKG inhibition (n=5). 
 
Figure 7. Inhibition of PKG prevents sGC stimulators from inhibiting TGFβ1-
induced collagen production in healthy fibroblasts. Levels of collagen protein (A) 
and COL1A1 mRNA (B) upon of pharmacological PKG inhibition (n=5). 
 
To exclude off-target effects of KT5823, we employed PKG1/PKG2 double 
knockout (PKG1/PKG2-dKO) fibroblasts explanted from PKG1/PKG2 double knockout 
mice. Combined knockout of PKG1 and PKG2 did not interfere with collagen release 
in resting fibroblasts. However, in contrast to wildtype fibroblasts, in PKG1/PKG2-dKO 
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fibroblasts BAY41-2272 could not inhibit TGFβ-induced upregulation of COL1A1 
mRNA and collagen protein (Fig. 8).  
 
Figure 8. PKG1/PKG2 double knockout (dKO) prevents sGC stimulators from 
inhibiting TGFβ1-induced collagen production in murine fibroblats. Levels of 
COL1A1 mRNA (A) and collagen protein (B) upon of pharmacological PKG inhibition 
(n=4).  
Taken together, these findings provide evidence that PKGs are essential 
downstream mediators of the antifibrotic effects of sGC stimulators. 
 
5.5. sGC-cGMP-PKG pathway interferes with fibroblast 
activation by modulating TGFβ-induced ERK activation 
We hypothesized that sGC stimulation and PKG inhibition modulate TGFβ-
induced fibroblast activation and collagen production by interfering with 
downstream TGFβ signaling. We first analyzed canonical SMAD signaling. However, 
neither sGC stimulation with BAY41-2272 nor the combination of sGC stimulation 
and PKG inhibition with KT5823 changed the activation of SMAD signaling: the 
levels of P-SMAD3, the SMAD-binding elements activity in reporter assays and the 
mRNA levels of the TGFβ/SMAD target gene SMAD7 did not change either in resting 
fibroblasts, or upon stimulation with TGFβ (Fig. 9). 
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Figure 9. sGC-cGMP-PKG signaling does not influence TGFβ1-induced SMAD 
activation in dermal fibroblasts. A, Representative Western Blots and B, 
quantification of P-SMAD3 levels, C, SBE reporter activity and D, mRNA levels of the 
SMAD target gene SMAD7. Fibroblasts were lysed 3 hours after TGFβ1 stimulation 
(n=5). 
 
 We next analyzed non-canonical downstream TGFβ signaling. Pharmacological 
stimulation of sGC with BAY41-2272 reduced TGFβ-induced activation of ERK and 
this effect was abrogated by co-incubation with the PKG inhibitor KT5823, 
highlighting the existence of a crosstalk between the sGC-cGMP-PKG signaling and 
non-canonical TGFβ signaling through ERK, likely responsible for the modulation of 
TGFβ-induced fibroblast activation by the drugs that target the sGC-cGMP-PKG 
pathway (Fig. 10).  
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Figure 10. sGC-cGMP-PKG signaling modulates TGFβ1-induced ERK activation in 
dermal fibroblasts. A, Representative Western Blots and B, quantification of P-ERK 
and total ERK. Fibroblasts were lysed 10 minutes after TGFβ1 stimulation (n = 6). 
 
Neither BAY41-2272, nor KT5823 interfered with TGFβ-induced activation of 
other mitogen-activated protein kinases (MAPK) such as JNK and P38 (Fig. 11).  
 
B A 
A B 
C 
D 
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Figure 11. sGC-cGMP-PKG signaling does not influence TGFβ1-induced activation 
of other MAPK signaling except ERK in dermal fibroblasts. Representative Western 
Blots (A, C) and quantifications (B, D) of P-JNK and total JNK (A-B), P-P38 and total 
P38 (C-D). Fibroblasts were lysed after 1 hour of TGFβ1 stimulation (n = 5). 
 
TGFβ-induced activation of the AP1 members cJUN and FRA2 was not influenced 
as well by pharmacological modulation of the sGC-cGMP-PKG pathway (Fig. 12). 
Similar results were observed for other non-canonical mediators of TGFβ signaling 
such as STAT3, SRC or AKT (Fig. 13).  
 
 
Figure 12. sGC-cGMP-PKG signaling does not influence TGFβ1-induced AP1 
activation. Representative Western Blots (A, C) and quantifications (B, D) of P-cJUN 
and cJUN total protein (A-B) and of FRA2 (C-D). Fibroblasts were lysed 3 hours for P-
cJUN – cJUN and 24 hours for FRA2 after TGFβ1 stimulation. 
A B 
C D 
32 
 
 
 
 
 
Figure 13. sGC-cGMP-PKG signaling does not influence TGFβ1-induced STAT3-, 
SRC- or AKT- activation. Representative Western Blots (A, C, E) and quantifications 
(B, D, F) of P-SRC and SRC (A-B), P-STAT3 and STAT3 (C-D), and P-AKT and AKT (E-F). 
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Fibroblasts were lysed after TGFβ1 stimulation: 1 hour for P-STAT3 – STAT3, 10 
minutes for P-SRC – SRC, 24 hours for P-AKT - AKT (n ≥ 3). 
 
5.6. Knockout of PKGs abrogates the antifibrotic effects of sGC 
stimulators 
We next aimed to study the role of PKGs as downstream mediators of the 
antifibrotic effects of sGC stimulators in experimental fibrosis. Although sGC 
stimulators exert potent antifibrotic effects, fibroblast-specific knockout of sGC did 
not render the mice more sensitive to bleomycin-induced skin fibrosis (Fig. 14). A 
likely explanation for this finding is the pronounced downregulation of sGC 
expression observed in fibroblasts in vitro in fibrotic conditions that could be present 
as well in fibroblasts in fibrotic murine skin. In theory, other cells beside fibroblasts 
can contribute to the antifibrotic effects of the sGC stimulator BAY41-2272. However, 
fibroblast-specific knockout of sGC abrogated these effects (Fig. 14), confirming that 
fibroblasts are major effector cells.  
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Figure 14. Fibroblast-specific knockout of sGC abrogates the antifibrotic effects of 
sGC stimulators in bleomycin-induced skin fibrosis. A, Representative trichrome 
stainings of the skin shown at 100-fold magnification. B, Dermal thickness. C, 
Myofibroblast counts. D, Hydroxyproline content. n ≥ 6 mice for all groups and 
outcomes. 
 
To evaluate the role of PKGs in the antifibrotic effects of sGC stimulators in vivo 
we generated mice with combined knockout of PKG1 and PKG2 
(PKG1fl/flxCol1a2;CreERxPKG2_KO). The skin of PKG1fl/flxCol1a2;CreERxPKG2_KO mice 
had normal architecture in the absence of profibrotic stimuli (Fig. 15). The sensitivity 
to bleomycin-induced fibrosis was similar between PKG1fl/flxCol1a2;CreERxPKG2_KO 
mice and control mice, further highlighting that the sGC-cGMP-PKG pathway is 
hypoactive in skin fibrosis and that the PKG upregulation fibrotic conditions is not 
paralleled by a higher PKG activity. However, the antifibrotic effects of sGC 
stimulation were abrogated in PKG1fl/flxCol1a2;CreERxPKG2_KO mice (Fig. 15), 
confirming that PKGs mediate them.       
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Figure 15. Combined knockout of PKG1 and PKG2 abrogates the antifibrotic effects 
of sGC stimulators in bleomycin-induced skin fibrosis. A, Representative trichrome 
stainings of the skin shown at 100× magnification. B, Dermal thickness. C, 
Myofibroblast counts. D, Hydroxyproline content. n≥6 mice for all groups and 
outcomes.  
 
6. Discussion 
 
In this work, we demonstrate that the sGC-cGMP-PKG pathway is hypoactive in 
SSc fibroblasts: sGC is downregulated and thus produces lower levels of cGMP (the 
main regulator of PKG activity), resulting in lower activation of PKGs with reduced 
VASP phosphorylation. sGC stimulators restore the sGC-cGMP-PKG signaling in SSc 
fibroblasts, providing further mechanistic rationale for their use in SSc. Although the 
sGC-cGMP-PKG pathway is hypoactive SSc fibroblasts, PKG1 and PKG2 are 
upregulated in a compensatory manner. The upregulation of PKGs could be a major 
contributor to the potent antifibrotic effects of sGC stimulators in SSc by amplifying 
minor increases in cGMP levels. 
We also show that aberrant TGFβ signaling in SSc may account for the reduced 
activation of sGC-cGMP-PKG pathway. Healthy dermal fibroblasts exposed to 
repetitive, long-term stimulation with recombinant TGFβ show alterations of sGC-
cGMP-PKG signaling similar to those observed in SSc fibroblasts. These findings, 
together with the inhibitory effects of sGC stimulation on TGFβ signaling, suggest a 
model in which TGFβ downregulates sGC-cGMP-PKG activity by reducing the sGC 
expression to facilitate its profibrotic effects. sGC stimulators disrupt this pathological 
signaling profile by restoring sufficient sGC-cGMP-PKG signaling to limit TGFβ 
signaling and its profibrotic effects.    
Using small molecule inhibitors and PKG knockout, we further demonstrate that 
PKGs are essentially required for the inhibitory effects of sGC stimulators on TGFβ-
induced fibroblast activation and collagen production in vitro. Double knockout of 
PKG1 and PKG2 also abrogated the antifibrotic effects of sGC stimulation in vivo, in a 
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model of bleomycin-induced skin fibrosis. Modulation of sGC-cGMP-PKG signaling 
interferes with the TGFβ-induced activation of ERK signaling (previously been shown 
to be hyperactive in systemic sclerosis and other fibrotic diseases), but not with  other 
downstream mediators of TGFβ signaling such as canonical SMAD or other non-
canonical pathways (Samuel et al. 2010; Nakerakanti and Trojanowska 2012). The 
selective modulation of TGFβ-induced ERK signaling may have implications for 
patient selection for treatment with sGC stimulators, since SSc patients with high 
TGFβ- and ERK activity at baseline might be better responders. To validate this 
hypothesis, additional studies on biopsies from the RISE-SSc trial are required. 
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